# Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

> **NCT03520647** · PHASE2 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 56 (estimated)

## Conditions studied

- Severe Aplastic Anemia (SAA)
- Hypo-Plastic Myelodysplastic Syndrome (MDS)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Cyclophosphamide
- **OTHER:** Peripheral Blood Stem Cells

## Key facts

- **NCT ID:** NCT03520647
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-02-19
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520647, "Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03520647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*